InMode (INMD) versus The Competition Critical Survey
InMode (NASDAQ: INMD) is one of 51 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its peers? We will compare InMode to similar businesses based on the strength of its institutional ownership, profitability, risk, earnings, analyst recommendations, valuation and dividends.
This table compares InMode and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares InMode and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|InMode||$156.36 million||$61.15 million||12.86|
|InMode Competitors||$1.12 billion||$126.03 million||16.22|
InMode’s peers have higher revenue and earnings than InMode. InMode is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
11.2% of InMode shares are owned by institutional investors. Comparatively, 47.2% of shares of all “Electromedical equipment” companies are owned by institutional investors. 15.5% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current ratings and price targets for InMode and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
InMode presently has a consensus price target of $45.25, suggesting a potential upside of 119.87%. As a group, “Electromedical equipment” companies have a potential upside of 65.30%. Given InMode’s stronger consensus rating and higher possible upside, analysts plainly believe InMode is more favorable than its peers.
InMode Company Profile
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.